NET PROFIT (x1000 DKK)
EMPLOYEES
Glucox Biotech AB
Closing information (x1000 DKK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
29
|
0
|
0 |
| Earnings before taxes |
-1,964
|
-1,141
|
-947 |
| EBITDA |
-529
|
-488
|
-462 |
| Total assets |
5,309
|
4,564
|
1,995 |
| Current assets |
248
|
267
|
144 |
| Current liabilities |
162
|
167
|
179 |
| Equity capital |
1,068
|
-1,163
|
-22 |
| - share capital |
1,009
|
1,043
|
1,038 |
| Employees (average) |
0
|
1
|
1 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
20.1%
|
-25.5%
|
-1.1% |
| Turnover per employee |
0
|
0 | |
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-36.4%
|
-25.0%
|
-47.5% |
| Current ratio |
153.1%
|
159.9%
|
80.4% |
| Return on equity (ROE) |
-183.9%
|
98.1%
|
4304.5% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
-1
|
0
|
0 |
| Chg. No. of employees % |
-100%
|
0%
|
0% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.